A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis.

Trial Profile

A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2014

At a glance

  • Drugs VB 201 (Primary)
  • Indications Atherosclerosis; Plaque psoriasis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 15 Dec 2014 Results published in a VBL Therapeutics media release.
    • 16 Mar 2012 Results were presented at the 70th Annual Meeting of the American Academy of Dermatology, according to a VBL Therapeutics media release. Results were also reported in the media release.
    • 15 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top